Key result
The ATLAS drug-eluting coronary stent demonstrated 100% interventional success with no restenosis or serious adverse events observed during the perioperative period.
Why the study?
Restenosis remains a significant issue after minimally invasive revascularization for CAD, leading to the use of drug-eluting stents to reduce restenosis rates.
Does the ATLAS Drug Eluting Coronary Stent System improve lumen diameter and prevent restenosis safely in patients with significant coronary artery stenosis?
Cohort (n=30)
No
Does the ATLAS Drug Eluting Coronary Stent System improve lumen diameter and prevent restenosis safely in patients with significant coronary artery stenosis?
The ATLAS drug-eluting coronary stent demonstrated preliminary perioperative safety and efficacy with favorable lumen diameter and no immediate restenosis in a small cohort.
Supports short-term safety in one case; leaves open need for larger trials to confirm efficacy.
Background : Coronary artery disease (CAD) is the most common type of heart disease. For its revascularization, minimally invasive techniques have been the preferred treatment modality for the past two decades. However, restenosis is a significant issue after these techniques. Drug-eluting stents (DES), primarily sirolimus or paclitaxel- releasing, have started to be widely used to reduce the rate of restenosis. Material Methods: 30 patients, 51-83 years old, who demonstrated significant coronary artery stenosis were treated with the The ATLAS Drug Eluting Coronary Stent System (AtlasPTCAⓇ; Invamed, Ankara, Turkey) at the Medical Simulation and Training Center, MU Plovdiv, Bulgaria. Accurate positioning of the stent, which contains radiopaque tungsten-tantalum markings at the tips, was traced by angiographical imaging. Measurements of vessel sizes before and after treatment were performed using quantitative coronary assessment (QCA). Quantitative analysis was performed by comparing the diameter of the reference vessel. Data were analyzed using IBM SPSS statistical package version 25 program. Result : After treatment, the final lumen diameter value was 3.45±0.56 mm, similar to the diameter measurement of the reference vessel. Restenosis was not observed in any of the patients. No serious side effects are observed. Conclusions AtlasPTCAⓇ is feasible and associated with a favorable profile of safety, efficacy, deliverability, and usability. Therefore, its use can provide a valuable aid in the treatment of coronary artery disease. For long-term evaluation, more studies are needed.
No takes yet. Share an insight, caveat, or question.
Aliman et al. (2023) conducted a cohort in Coronary artery disease (n=30). ATLAS Drug Eluting Coronary Stent System was evaluated on Device-related adverse events and serious adverse events during hospitalization. The ATLAS drug-eluting coronary stent demonstrated 100% interventional success with no restenosis or serious adverse events observed during the perioperative period.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: